Denali Therapeutics Inc.
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership1,310,656 shares
Latest Disclosed Value $ 25,164,596
Northern Trust Corp reports 9.24% increase in ownership of DNLI / Denali Therapeutics Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 1,310,656 shares of Denali Therapeutics Inc. (US:DNLI) valued at $25,164,595 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,199,744 shares of Denali Therapeutics Inc.. This represents a change in shares of 9.24% during the quarter. The current value of the position is $26,396,612 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,310,656 110,912 9.24 25,165 27.05 0.0007
2026-02-17 2025-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,199,744 -34,435 -2.79 19,808 10.53 0.0005
2025-11-14 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,234,179 32,470 2.70 17,920 6.60 0.0023
2025-08-13 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,201,709 69,536 6.14 16,812 9.23 0.0023
2025-05-13 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,132,173 -69,345 -5.77 15,392 -37.14 0.0023
2025-02-14 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,201,518 115,876 10.67 24,487 -22.57 0.0035
2024-11-13 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,085,642 2,683 0.25 31,625 25.76 0.0052
2024-08-14 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,082,959 -5,554 -0.51 25,146 12.58 0.0042
2024-05-14 2024-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,088,513 -13,166 -1.20 22,336 -5.52 0.0039
2024-02-13 2023-12-31 13F DENALI THERAPEUTICS COM 24823R105 1,101,679 -15,063 -1.35 23,642 2.62 0.0043
2023-11-13 2023-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,116,742 27,044 2.48 23,038 -28.36 0.0045
2023-08-11 2023-06-30 13F DENALI THERAPEUTICS COM 24823R105 1,089,698 71,694 7.04 32,157 37.10 0.0062
2023-05-15 2023-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,018,004 33,813 3.44 23,455 -14.31 0.0047
2023-02-13 2022-12-31 13F DENALI THERAPEUTICS COM 24823R105 984,191 94,223 10.59 27,370 0.21 0.0057
2022-11-14 2022-09-30 13F DENALI THERAPEUTICS COM 24823R105 889,968 -650 -0.07 27,313 4.21 0.0062
2022-08-12 2022-06-30 13F DENALI THERAPEUTICS COM 24823R105 890,618 -15,610 -1.72 26,210 -10.10 0.0056
2022-05-13 2022-03-31 13F DENALI THERAPEUTICS COM 24823R105 906,228 -52,861 -5.51 29,153 -31.85 0.0051
2022-02-08 2021-12-31 13F DENALI THERAPEUTICS COM 24823R105 959,089 7,364 0.77 42,775 -10.92 0.0070
2021-11-15 2021-09-30 13F DENALI THERAPEUTICS COM 24823R105 951,725 -27,333 -2.79 48,016 -37.48 0.0085
2021-08-13 2021-06-30 13F DENALI THERAPEUTICS COM 24823R105 979,058 225,424 29.91 76,798 78.46 0.0135
2021-05-12 2021-03-31 13F DENALI THERAPEUTICS COM 24823R105 753,634 -24,111 -3.10 43,033 -33.94 0.0080
2021-02-11 2020-12-31 13F DENALI THERAPEUTICS COM 24823R105 777,745 -11,273 -1.43 65,145 130.44 0.0127
2020-11-16 2020-09-30 13F DENALI THERAPEUTICS COM 24823R105 789,018 -43,242 -5.20 28,270 40.47 0.0062
2020-08-14 2020-06-30 13F DENALI THERAPEUTICS COM 24823R105 832,260 134,061 19.20 20,125 64.62 0.0048
2020-05-14 2020-03-31 13F DENALI THERAPEUTICS COM 24823R105 698,199 63,187 9.95 12,225 10.51 0.0035
2020-02-14 2019-12-31 13F DENALI THERAPEUTICS COM 24823R105 635,012 -19,439 -2.97 11,062 10.32 0.0025
2019-11-13 2019-09-30 13F DENALI THERAPEUTICS COM 24823R105 654,451 34,401 5.55 10,027 -22.11 0.0024
2019-08-13 2019-06-30 13F DENALI THERAPEUTICS COM 24823R105 620,050 6,063 0.99 12,873 -9.71 0.0031
2019-05-13 2019-03-31 13F DENALI THERAPEUTICS COM 24823R105 613,987 23 0.00 14,257 12.39 0.0035
2019-02-12 2018-12-31 13F DENALI THERAPEUTICS COM 24823R105 613,964 14,105 2.35 12,685 -2.73 0.0036
2018-11-14 2018-09-30 13F DENALI THERAPEUTICS COM 24823R105 599,859 412,925 220.89 13,041 357.58 0.0032
2018-09-18 2018-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 186,934 18,885 11.24 2,850 -13.87 0.0007
2018-08-14 2018-06-30 13F DENALI THERAPEUTICS COM 24823R105 186,934 18,885 2,850
2018-05-09 2018-03-31 13F DENALI THERAPEUTICS COM 24823R105 168,049 168,049 3,309 0.0009
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.